IRVINE, Calif., Jan. 25, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries announced today that its BluScience (www.bluscience.com) line of dietary supplements is now being distributed by McKesson to approximately 4,000 independent drugstores and pharmacies. McKesson is the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day.
McKesson is now distributing three BluScience SKUs:
Commenting on the announcement, Jeff Himmel, CEO of ChromaDex, stated "The nationwide launch of BluScience continues to gain momentum. During the month of January alone, BluScience became available at a national drug store chain with more than 8,000 stores throughout the United States as well as the prominent online retailer, Drugstore.com. These outlets complemented our initial launch into GNC. Through our new relationship with McKesson, we add approximately 4,000 independent drugstores and pharmacies selling BluScience. We expect BluScience to be available in more than 25,000 retail stores by year-end 2012, as well as through major online retailers."
The novel ingredient in BluScience is ChromaDex's proprietary, patent-pending pterostilbene, branded as pTeroPure® (www.pteropure.com), which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.
pTeroPure is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (an antioxidant phytochemical that tends to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.
McKesson Corporation (NYSE: MCK) currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.
For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Liviakis Financial Communications, Inc.
John M. Liviakis, President
Institutions and Analysts Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Jeffrey Himmel, CEO
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
|SOURCE ChromaDex Corporation|
Copyright©2010 PR Newswire.
All rights reserved